Uterine sarcomas are relatively rare tumors with a dismal survival rate of 30–40 %. Fifty percent of women present in FIGO stage I . Most of the tumors spread hematogenously, resulting in an extremely poor prognosis in advanced stages. Even in the early stages (FIGO stage I–II), 35 % of patients fail locally and 65 % fail in distant sites [2, 3]. Radiotherapy to pelvis is given usually as an adjuvant therapy with an aim to decrease local recurrence.
KeywordsAdjuvant Radiotherapy Figo Stage Uterine Sarcoma Endometrial Stromal Sarcoma Good Local Control
- 4.Harlow BL, Weiss NS, Lofton S. The epidemiology of sarcomas of the uterus. J Natl Cancer Inst. 1986;76(3):339–402.Google Scholar
- 5.WHO. Pathology and genetics of tumors of the breast and female genital organs. Lyon: IARC Press; 2003.Google Scholar
- 8.Pautier P, Rey A, Haie-Meder C, Kerbrat P, Dutel JL, Gesta P, et al. Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case-control study with radiotherapy alone. Int J Gynecol Cancer. 2004;14:1112–7.CrossRefPubMedGoogle Scholar
- 14.Wolfson AH, Brady MF, Rocereto T, et al. A Gynecologic Oncology Group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol. 2007;107:177–85.PubMedCentralCrossRefPubMedGoogle Scholar
- 15.Reed NS, Mangioni C, Malmström H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organization for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008;44(6):808–18.CrossRefPubMedGoogle Scholar
- 23.NCCN guidelines version 1.2015, MS 18–20.Google Scholar